Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Eribulin + Pembrolizumab |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | triple-receptor negative breast cancer | predicted - sensitive | Eribulin + Pembrolizumab | Phase Ib/II | Actionable | In a Phase I/II trial, Keytruda (pembrolizumab) and Eribulin combination therapy demonstrated safety and clinical activity in patients with metastatic triple-negative breast cancer, patients with CD274 (PD-L1)-positive tumors achieved better objective response rate (28.4% vs 17.3%), median progression-free survival (4.2 vs 3.9 months), and overall survival (16.3 vs 15.2 months) compared to patients with CD274 (PD-L1)-negative tumors (PMID: 33727258; NCT02513472). | 33727258 |
PubMed Id | Reference Title | Details |
---|---|---|
(33727258) | Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. | Full reference... |